Response to the letter titled "Targeting dementia prevention with semaglutide: the case for APOE4 homozygotes"

Rong Xu¹

Affiliations

Rong Xu. Alzheimers Dement. 2025 Jun.

. 2025 Jun;21(6):e70423.

doi: 10.1002/alz.70423.

Rong Xu¹

¹ Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.

No abstract available

Conflict of interest statement

The author declares no conflicts of interest. Author disclosures are available in the supporting information.

1. Wang W, Wang Q, Qi X, et al. Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real‐world data in the US. Alzheimers Dement. 2024;20(12):8661‐8672. doi: 10.1002/alz.14313 - DOI - PMC - PubMed
1. Serrano‐Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68‐80. - PMC - PubMed
1. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet. 2024;404(10452):572‐628. - PubMed
1. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138‐150. - PMC - PubMed
1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834‐1144. - PubMed